Progenics Pharmaceuticals Inc. (PGNX) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE WORLD TRADE CENTER
NEW YORK, NY 10007
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2020
MRQ
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 42,049137,68690,642138,90974,103119,302
Cash and cash equivalents 42,049137,68690,642138,90974,103119,302
Receivables 15,9763,8033,9724,8643,543109
Other current assets 5,7072,6402,2564,3285,6392,515
Total current assets: 63,732144,12996,870148,10183,285121,926
Noncurrent Assets
Operating lease, right-of-use asset 13,493
Property, plant and equipment 11,6883,9444,1224,7602,4072,552
Intangible assets, net (including goodwill) 24,67019,74043,44343,65543,86736,402
Goodwill 17,84713,07413,07413,07413,0747,702
Intangible assets, net (excluding goodwill) 6,8236,66630,36930,58130,79328,700
Other noncurrent assets 5,8871,6841,5222,4701,692157
Total noncurrent assets: 55,73825,36849,08750,88547,96639,111
TOTAL ASSETS: 119,470169,497145,957198,986131,251161,037
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 14,35210,97712,91416,3319,5446,570
Employee-related liabilities     1,8451,722
Accounts payable 1,2494443,3595674521,040
Accrued liabilities 13,10310,5339,55515,7644,2871,146
Other undisclosed accounts payable and accrued liabilities     2,9602,662
Debt 7,7165,4192,445   
Business combination, contingent consideration, liability  7,050    
Other liabilities    26185115
Total current liabilities: 22,06823,44615,35916,3579,7296,685
Noncurrent Liabilities
Long-term debt and lease obligation 46,91539,18047,24249,453  
Long-term debt, excluding current maturities 31,91039,18047,24249,453  
Liabilities, other than long-term debt 3,9345,76819,55316,28020,06418,447
Deferred revenue and credits1,225876402336
Deferred income tax liabilities 34
Other liabilities  1,8181,5281,204862911
Operating lease, liability 15,005
Business combination, contingent consideration, liability 3,9003,95016,80014,20018,80017,200
Other undisclosed noncurrent liabilities  2835012,13410,79710,996
Total noncurrent liabilities: 50,84944,97667,14577,86730,86129,443
Total liabilities: 72,91768,42282,50494,22440,59036,128
Equity
Equity, attributable to parent 46,553101,07563,453104,76290,456124,909
Common stock 11311093929191
Treasury stock, value (2,741)(2,741)(2,741)(2,741)(2,741)(2,741)
Common stock, share subscribed but unissued, subscriptions receivable   (2,109)   
Additional paid in capital 727,089713,019609,829598,069594,511589,826
Accumulated other comprehensive loss (148)(105)(33)(85)(26) 
Accumulated deficit (677,760)(609,208)(541,586)(490,573)(501,379)(462,267)
Equity, attributable to noncontrolling interest     205 
Total equity: 46,553101,07563,453104,76290,661124,909
TOTAL LIABILITIES AND EQUITY: 119,470169,497145,957198,986131,251161,037

Income Statement (P&L) ($ in thousands)

3/31/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 34,98615,62211,69869,4298,67644,377
Revenue, net11,69869,4298,67644,377
Other operating income      7,250
Cost of revenue (4,084)    (498)
Cost of goods and services sold (3,168)    (498)
Gross profit: 30,90215,62211,69869,4298,67643,879
Operating expenses (97,061)(81,978)(70,098)(56,325)(47,980)(48,257)
Other undisclosed operating income      7,748
Operating income (loss): (66,159)(66,356)(58,400)13,104(39,304)3,370
Nonoperating income (expense) (2,376)(2,933)(4,285)(527)5251
Investment income, nonoperating     5251
Income (loss) from continuing operations before income taxes: (68,535)(69,289)(62,685)12,577(39,252)3,421
Income tax expense (benefit) (17)1,63211,672(1,844)133989
Income (loss) from continuing operations: (68,552)(67,657)(51,013)10,733(39,119)4,410
Income (loss) before gain (loss) on sale of properties: (68,552)(67,657)(51,013)10,733(39,119)4,410
Net income (loss): (68,552)(67,657)(51,013)10,733(39,119)4,410
Net income attributable to noncontrolling interest    737 
Net income (loss) available to common stockholders, diluted: (68,552)(67,657)(51,013)10,806(39,112)4,410

Comprehensive Income ($ in thousands)

3/31/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss): (68,552)(67,657)(51,013)10,733(39,119)4,410
Other comprehensive income (loss)    (62)(26)192
Other undisclosed comprehensive income (loss)  (72)52   
Comprehensive income (loss): (68,552)(67,729)(50,961)10,671(39,145)4,602
Comprehensive income, net of tax, attributable to noncontrolling interest    737 
Other undisclosed comprehensive loss, net of tax, attributable to parent (43)     
Comprehensive income (loss), net of tax, attributable to parent: (68,595)(67,729)(50,961)10,744(39,138)4,602

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: